Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE

被引：5

作者：

Verma, S ^{[1
]}

Leiter, LA

Lonn, EM

Straus, MH

机构：

[1] St Michaels Hosp, Div Cardiac Surg, Toronto, ON M5G 2CA, Canada

[2] Univ Toronto, Toronto Gen Hosp, Toronto, ON M5G 2CA, Canada

[3] St Michaels Hosp, Div Endocrinol, Toronto, ON M5B 1W8, Canada

[4] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada

[5] McMaster Univ, Div Cardiol, Hamilton, ON, Canada

[6] N York Gen Hosp, Div Cardiol, Toronto, ON, Canada

来源：

EUROPEAN HEART JOURNAL | 2005年 / 26卷 / 14期

关键词：

D O I：

10.1093/eurheartj/ehi308

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This editorial refers to 'The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy'(dagger) by C. Daly et al., on page 1369.

引用

页码：1347 / 1349

页数：3

共 15 条

[1] Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [J].

Barnett, AH ;

Bain, SC ;

Bouter, P ;

Karlberg, B ;

Madsbad, S ;

Jervell, J ;

Mustonen, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1952-1961

[2]

Braunwald E, 2004, NEW ENGL J MED, V351, P2058

[3] Atenolol in hypertension: is it a wise choice? [J].

Carlberg, B ;

Samuelsson, O ;

Lindholm, LJ .

LANCET, 2004, 364 (9446) :1684-1689

[4] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].

Colhoun, HM ;

Betteridge, DJ ;

Durrington, PN ;

Hitman, GA ;

Neil, HAW ;

Livingstone, SJ ;

Thomason, MJ ;

Mackness, MI ;

Charlton-Menys, V ;

Fuller, JH .

LANCET, 2004, 364 (9435) :685-696

[5] The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy [J].

Daly, CA ;

Fox, KM ;

Remme, WJ ;

Bertrand, ME ;

Ferrari, R ;

Simoons, ML .

EUROPEAN HEART JOURNAL, 2005, 26 (14) :1369-1378

[6] Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [J].

Gaede, P ;

Vedel, P ;

Larsen, N ;

Jensen, GVH ;

Parving, H ;

Pedersen, O .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) :383-393

[7]

Gerstein HC, 2000, LANCET, V355, P253

[8] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].

Lewis, EJ ;

Hunsicker, LG ;

Clarke, WR ;

Berl, T ;

Pohl, MA ;

Lewis, JB ;

Ritz, E ;

Atkins, RC ;

Rohde, R ;

Raz, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860

[9] THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON DIABETIC NEPHROPATHY [J].

LEWIS, EJ ;

HUNSICKER, LG ;

BAIN, RP ;

ROHDE, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (20) :1456-1462

[10] Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease -: The task force on ACE-inhibitors of the European Society of Cardiolgy [J].

López-Sendón, J ;

Swedberg, K ;

McMurray, J ;

Tamargo, J ;

Maggioni, AP ;

Dargie, H ;

Tendere, M ;

Waagstein, F ;

Kjekshus, J ;

Lechat, P ;

Torp-Pedersen, C .

EUROPEAN HEART JOURNAL, 2004, 25 (16) :1454-1470

← 1 2 →